These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 10820893)

  • 21. The role of thromboxane A2 in increased whole blood platelet aggregation in oral contraceptive users.
    Norris LA; Devitt M; Bonnar J
    Thromb Res; 1996 Feb; 81(4):407-17. PubMed ID: 8907290
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. Transnational Research Group on Oral Contraceptives and the Health of Young Women.
    Spitzer WO; Lewis MA; Heinemann LA; Thorogood M; MacRae KD
    BMJ; 1996 Jan; 312(7023):83-8. PubMed ID: 8555935
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effect of oestrogen dose and progestogen type on haemostatic changes in women taking low dose oral contraceptives.
    Norris LA; Bonnar J
    Br J Obstet Gynaecol; 1996 Mar; 103(3):261-7. PubMed ID: 8630312
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Desogestrel, norgestimate, and gestodene: the newer progestins.
    Kaplan B
    Ann Pharmacother; 1995; 29(7-8):736-42. PubMed ID: 8520092
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pill research results in new guidance from CSM.
    Fam Plann Today; 1995; ():1. PubMed ID: 12319465
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The increased risk of venous thromboembolism and the use of third generation progestagens: role of bias in observational research. The Transnational Research Group on Oral Contraceptives and the Health of Young Women.
    Lewis MA; Heinemann LA; MacRae KD; Bruppacher R; Spitzer WO
    Contraception; 1996 Jul; 54(1):5-13. PubMed ID: 8804801
    [TBL] [Abstract][Full Text] [Related]  

  • 27. European Society of Contraception oral contraceptives survey update: birth control methods in "Europe of the 12".
    Serfaty D; Wildemeersch D; Verougstraete A; Creatsas G
    Int J Fertil Menopausal Stud; 1995; 40 Suppl 2():73-9. PubMed ID: 8574253
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New progestogens in oral contraceptives.
    Runnebaum B; Rabe T
    Am J Obstet Gynecol; 1987 Oct; 157(4 Pt 2):1059-63. PubMed ID: 2960242
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cardiovascular events associated with different combined oral contraceptives: a review of current data.
    Hannaford P
    Drug Saf; 2000 May; 22(5):361-71. PubMed ID: 10830253
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Oral contraception and venous thromboembolism. A New Zealand perspective.
    Roke C
    Drug Saf; 1997 Feb; 16(2):79-87. PubMed ID: 9067120
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Metabolic profile of six oral contraceptives containing norgestimate, gestodene, and desogestrel.
    Teichmann A
    Int J Fertil Menopausal Stud; 1995; 40 Suppl 2():98-104. PubMed ID: 8574257
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Characteristics of the new progestogens in combination oral contraceptives.
    Rebar RW; Zeserson K
    Contraception; 1991 Jul; 44(1):1-10. PubMed ID: 1832625
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Omitting the first oral contraceptive pills of the cycle does not automatically lead to ovulation.
    Elomaa K; Rolland R; Brosens I; Moorrees M; Deprest J; Tuominen J; Lähteenmäki P
    Am J Obstet Gynecol; 1998 Jul; 179(1):41-6. PubMed ID: 9704763
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Influence of gestodene and desogestrel as components of low-dose oral contraceptives on the pharmacokinetics of ethinyl estradiol (EE2), on serum CBG and on urinary cortisol and 6 beta-hydroxycortisol.
    Hammerstein J; Daume E; Simon A; Winkler UH; Schindler AE; Back DJ; Ward S; Neiss A
    Contraception; 1993 Mar; 47(3):263-81. PubMed ID: 8462317
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cardiovascular safety of oral contraceptives. What has changed in the last decade?
    Ory HW
    Contraception; 1998 Sep; 58(3 Suppl):9S-13S; quiz 65S. PubMed ID: 9807687
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The use of a large-scale surveillance system in Planned Parenthood Federation of America clinics to monitor cardiovascular events in users of combination oral contraceptives.
    Burnhill MS
    Int J Fertil Womens Med; 1999; 44(1):19-30. PubMed ID: 10206196
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical risk factors for venous thromboembolus in users of the combined oral contraceptive pill.
    Black C; Kaye JA; Jick H
    Br J Clin Pharmacol; 2002 Jun; 53(6):637-40. PubMed ID: 12047488
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Oral contraceptive pills and the risk of venous thromboembolism.
    Prog Hum Reprod Res; 1996; (39):2-3. PubMed ID: 12292198
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparative pharmacology of newer progestogens.
    Kuhl H
    Drugs; 1996 Feb; 51(2):188-215. PubMed ID: 8808163
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Venous thromboembolic disease and combined oral contraceptives: A re-analysis of the MediPlus database.
    Todd J; Lawrenson R; Farmer RD; Williams TJ; Leydon GM
    Hum Reprod; 1999 Jun; 14(6):1500-5. PubMed ID: 10357966
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.